从临床批准的药物中识别烯碳化合物受体全抗体
Farag E S Mosa1, Mohammed A Alqahtani1, Mahmoud A El-Ghiaty1
1Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
尼罗丁尼是FDA批准的药物,作为阿里碳化合物受体 (AhR) 的非竞争性全抗体. 它通过防止异构体的形成来阻止AhR信号传递,为AhR介导的疾病提供新的治疗潜力.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 人类的酸受体 (AhR) 是各种生物和病理生理过程中至关重要的转录因子.
- 由于其在致癌和抗瘤策略中的作用,AhR是癌症治疗的重要目标.
研究的目的:
- 通过计算选FDA批准的药物,这些药物与AhR的全位结合.
- 为潜在的治疗应用确定AhR正规通路活性的抑制剂.
主要方法:
- 利用计算机建模来选与AhR全位结合的药物.
- 进行分子动力学 (MD) 模拟,以评估药物向相互作用和稳定性.
- 研究了已识别的药物对AhR核转位和异构体形成的影响.
主要成果:
- 尼罗丁尼被确定为AhR全囊的强有力的结合剂,与关键残留物相互作用.
- 在MD模拟过程中,尼罗丁尼表现出最低的结合自由能量和稳定的相互作用.
- 尼罗丁尼抑制了AhR-ARNT-DNA异构聚合,并阻止了像CYP1A1这样的基因的上调调节,而不会影响核转位.
结论:
- 尼罗丁尼作为AhR信号通路的非竞争性全抗体.
- 尼罗丁尼通过PAS-B域调节AhR活性,提供了一种新的治疗策略.
- 这些发现表明,尼洛丁尼可用于涉及AhR的疾病的重新定位.
更多相关视频
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
相关概念视频
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Drug-Receptor Interactions
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
